{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:42:46Z","timestamp":1778193766279,"version":"3.51.4"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s12016-008-8085-y","type":"journal-article","created":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T18:01:27Z","timestamp":1219773687000},"page":"52-61","source":"Crossref","is-referenced-by-count":27,"title":["Medical Treatment of Primary Sclerosing Cholangitis: A Role for Novel Bile Acids and other (post-)Transcriptional Modulators?"],"prefix":"10.1007","volume":"36","author":[{"given":"Ulrich","family":"Beuers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd A.","family":"Kullak-Ublick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pusl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik R.","family":"Rauws","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Rust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"issue":"3","key":"8085_CR1","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hep.21337","volume":"44","author":"NF LaRusso","year":"2006","unstructured":"LaRusso NF, Shneider BL, Black D et al (2006) Primary sclerosing cholangitis: summary of a workshop. Hepatology 44(3):746\u2013764","journal-title":"Hepatology"},{"issue":"1","key":"8085_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2006-933559","volume":"26","author":"CA O\u2019Mahony","year":"2006","unstructured":"O\u2019Mahony CA, Vierling JM (2006) Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis 26(1):3\u201321","journal-title":"Semin Liver Dis"},{"issue":"2","key":"8085_CR3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1385\/CRIAI:28:2:093","volume":"28","author":"J Worthington","year":"2005","unstructured":"Worthington J, Cullen S, Chapman R (2005) Immunopathogenesis of primary sclerosing cholangitis. Clin Rev Allergy Immunol 28(2):93\u2013103","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"8085_CR4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nri1784","volume":"6","author":"DH Adams","year":"2006","unstructured":"Adams DH, Eksteen B (2006) Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 6(3):244\u2013251","journal-title":"Nat Rev Immunol"},{"issue":"17","key":"8085_CR5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM199810223391707","volume":"339","author":"M Trauner","year":"1998","unstructured":"Trauner M, Meier PJ, Boyer JL (1998) Molecular pathogenesis of cholestasis. N Engl J Med 339(17):1217\u20131227","journal-title":"N Engl J Med"},{"issue":"28","key":"8085_CR6","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.3748\/wjg.v12.i28.4445","volume":"12","author":"G Paumgartner","year":"2006","unstructured":"Paumgartner G (2006) Medical treatment of cholestatic liver diseases: from pathobiology to pharmacological targets. World J Gastroenterol 12(28):4445\u20134451","journal-title":"World J Gastroenterol"},{"issue":"2","key":"8085_CR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0009-8981(96)06305-X","volume":"251","author":"S Fischer","year":"1996","unstructured":"Fischer S, Beuers U, Spengler U, Zwiebel FM, Koebe HG (1996) Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin Chim Acta 251(2):173\u2013186","journal-title":"Clin Chim Acta"},{"issue":"6","key":"8085_CR8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/hep.510280601","volume":"28","author":"U Beuers","year":"1998","unstructured":"Beuers U, Boyer JL, Paumgartner G (1998) Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications. Hepatology 28(6):1449\u20131453","journal-title":"Hepatology"},{"issue":"2","key":"8085_CR9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1152\/physrev.00027.2002","volume":"83","author":"M Trauner","year":"2003","unstructured":"Trauner M, Boyer JL (2003) Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 83(2):633\u2013671","journal-title":"Physiol Rev"},{"issue":"3","key":"8085_CR10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jhep.2006.12.001","volume":"46","author":"JL Boyer","year":"2007","unstructured":"Boyer JL (2007) New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J Hepatol 46(3):365\u2013371","journal-title":"J Hepatol"},{"issue":"6","key":"8085_CR11","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1073\/pnas.0409794102","volume":"102","author":"CA Stedman","year":"2005","unstructured":"Stedman CA, Liddle C, Coulter SA et al (2005) Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury. Proc Natl Acad Sci U S A 102(6):2063\u20132068","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"8085_CR12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1021\/mp060010s","volume":"3","author":"G Zollner","year":"2006","unstructured":"Zollner G, Marschall HU, Wagner M, Trauner M (2006) Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm 3(3):231\u2013251","journal-title":"Mol Pharm"},{"issue":"3","key":"8085_CR13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","volume":"36","author":"A Bergquist","year":"2002","unstructured":"Bergquist A, Ekbom A, Olsson R et al (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36(3):321\u2013327","journal-title":"J Hepatol"},{"issue":"1","key":"8085_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/hep.21964","volume":"47","author":"E Melum","year":"2008","unstructured":"Melum E, Karlsen TH, Schrumpf E et al (2008) Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 47(1):90\u201396","journal-title":"Hepatology"},{"issue":"41","key":"8085_CR15","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.3748\/wjg.v13.i41.5421","volume":"13","author":"TH Karlsen","year":"2007","unstructured":"Karlsen TH, Schrumpf E, Boberg KM (2007) Genetic epidemiology of primary sclerosing cholangitis. World J Gastroenterol 13(41):5421\u20135431","journal-title":"World J Gastroenterol"},{"issue":"5","key":"8085_CR16","first-page":"1404","volume":"22","author":"U Broome","year":"1995","unstructured":"Broome U, Lofberg R, Veress B, Eriksson LS (1995) Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22(5):1404\u20131408","journal-title":"Hepatology"},{"issue":"12","key":"8085_CR17","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/01.TP.0000058744.34965.38","volume":"75","author":"A Vera","year":"2003","unstructured":"Vera A, Gunson BK, Ussatoff V et al (2003) Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75(12):1983\u20131988","journal-title":"Transplantation"},{"issue":"3","key":"8085_CR18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.510270308","volume":"27","author":"EV Loftus Jr","year":"1998","unstructured":"Loftus EV Jr, Aguilar HI, Sandborn WJ et al (1998) Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 27(3):685\u2013690","journal-title":"Hepatology"},{"issue":"2","key":"8085_CR19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.1840220213","volume":"22","author":"S Narumi","year":"1995","unstructured":"Narumi S, Roberts JP, Emond JC, Lake J, Ascher NL (1995) Liver transplantation for sclerosing cholangitis. Hepatology 22(2):451\u2013457","journal-title":"Hepatology"},{"issue":"1","key":"8085_CR20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mge.2002.125367","volume":"56","author":"RM Soetikno","year":"2002","unstructured":"Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56(1):48\u201354","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"8085_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF02234825","volume":"44","author":"BU Lindberg","year":"2001","unstructured":"Lindberg BU, Broome U, Persson B (2001) Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 44(1):77\u201385","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"8085_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","volume":"54","author":"EV Loftus Jr","year":"2005","unstructured":"Loftus EV Jr, Harewood GC, Loftus CG et al (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54(1):91\u201396","journal-title":"Gut"},{"issue":"1","key":"8085_CR23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-2006-933563","volume":"26","author":"SN Cullen","year":"2006","unstructured":"Cullen SN, Chapman RW (2006) The medical management of primary sclerosing cholangitis. Semin Liver Dis 26(1):52\u201361","journal-title":"Semin Liver Dis"},{"issue":"3","key":"8085_CR24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/hep.1840160315","volume":"16","author":"U Beuers","year":"1992","unstructured":"Beuers U, Spengler U, Kruis W et al (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16(3):707\u2013714","journal-title":"Hepatology"},{"issue":"1","key":"8085_CR25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0168-8278(05)80467-2","volume":"20","author":"A Stiehl","year":"1994","unstructured":"Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L (1994) Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 20(1):57\u201364","journal-title":"J Hepatol"},{"issue":"10","key":"8085_CR26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","volume":"336","author":"KD Lindor","year":"1997","unstructured":"Lindor KD (1997) Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336(10):691\u2013695","journal-title":"N Engl J Med"},{"issue":"4","key":"8085_CR27","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","volume":"121","author":"SA Mitchell","year":"2001","unstructured":"Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW (2001) A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121(4):900\u2013907","journal-title":"Gastroenterology"},{"issue":"5","key":"8085_CR28","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","volume":"129","author":"R Olsson","year":"2005","unstructured":"Olsson R, Boberg KM, de Muckadell OS et al (2005) High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 129(5):1464\u20131472","journal-title":"Gastroenterology"},{"issue":"5","key":"8085_CR29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","volume":"48","author":"SN Cullen","year":"2008","unstructured":"Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman R (2008) High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 48(5):792\u2013800","journal-title":"J Hepatol"},{"issue":"5","key":"8085_CR30","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1572-0241.2001.03777.x","volume":"96","author":"DM Harnois","year":"2001","unstructured":"Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD (2001) High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 96(5):1558\u20131562","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"8085_CR31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jhep.2004.01.002","volume":"40","author":"B Brandsaeter","year":"2004","unstructured":"Brandsaeter B, Isoniemi H, Broome U et al (2004) Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 40(5):815\u2013822","journal-title":"J Hepatol"},{"issue":"4","key":"8085_CR32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2003.50156","volume":"124","author":"DS Pardi","year":"2003","unstructured":"Pardi DS, Loftus EV Jr., Kremers WK, Keach J, Lindor KD (2003) Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 124(4):889\u2013893","journal-title":"Gastroenterology"},{"issue":"2","key":"8085_CR33","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-134-2-200101160-00008","volume":"134","author":"BY Tung","year":"2001","unstructured":"Tung BY, Emond MJ, Haggitt RC et al (2001) Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 134(2):89\u201395","journal-title":"Ann Intern Med"},{"issue":"6","key":"8085_CR34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","volume":"3","author":"U Beuers","year":"2006","unstructured":"Beuers U (2006) Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nature Clin Pract Gastroenterol Hepatol 3(6):318\u2013328","journal-title":"Nature Clin Pract Gastroenterol Hepatol"},{"issue":"3","key":"8085_CR35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","volume":"36","author":"G Paumgartner","year":"2002","unstructured":"Paumgartner G, Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36(3):525\u2013531","journal-title":"Hepatology"},{"issue":"1","key":"8085_CR36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0168-8278(01)00092-7","volume":"35","author":"KN Lazaridis","year":"2001","unstructured":"Lazaridis KN, Gores GJ, Lindor KD (2001) Ursodeoxycholic acid \u2018mechanisms of action and clinical use in hepatobiliary disorders\u2019. J Hepatol 35(1):134\u2013146","journal-title":"J Hepatol"},{"issue":"3","key":"8085_CR37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2006.05.057","volume":"131","author":"TH Karlsen","year":"2006","unstructured":"Karlsen TH, Lie BA, Frey Froslie K et al (2006) Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 131(3):781\u2013787","journal-title":"Gastroenterology"},{"issue":"3","key":"8085_CR38","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/gut.2005.067389","volume":"55","author":"P Hruz","year":"2006","unstructured":"Hruz P, Zimmermann C, Gutmann H et al (2006) Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut 55(3):395\u2013402","journal-title":"Gut"},{"issue":"3","key":"8085_CR39","first-page":"283","volume":"23","author":"A Stiehl","year":"1995","unstructured":"Stiehl A, Rudolph G, Sauer P, Theilmann L (1995) Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol 23(3):283\u2013289","journal-title":"J Hepatol"},{"issue":"1","key":"8085_CR40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/jhep.2003.50311","volume":"38","author":"L Serfaty","year":"2003","unstructured":"Serfaty L, De Leusse A, Rosmorduc O et al (2003) Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 38(1):203\u2013209","journal-title":"Hepatology"},{"issue":"2","key":"8085_CR41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","volume":"130","author":"P Fickert","year":"2006","unstructured":"Fickert P, Wagner M, Marschall HU et al (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130(2):465\u2013481","journal-title":"Gastroenterology"},{"issue":"6","key":"8085_CR42","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20943","volume":"42","author":"AF Hofmann","year":"2005","unstructured":"Hofmann AF, Zakko SF, Lira M et al (2005) Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42(6):1391\u20131398","journal-title":"Hepatology"},{"issue":"5418","key":"8085_CR43","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ et al (1999) Identification of a nuclear receptor for bile acids. Science 284(5418):1362\u20131365","journal-title":"Science"},{"issue":"5418","key":"8085_CR44","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks DJ, Blanchard SG, Bledsoe RK et al (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284(5418):1365\u20131368","journal-title":"Science"},{"issue":"1","key":"8085_CR45","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cld.2007.11.013","volume":"12","author":"G Paumgartner","year":"2008","unstructured":"Paumgartner G, Pusl T (2008) Medical treatment of cholestatic liver disease. Clin Liver Dis 12(1):53\u201380","journal-title":"Clin Liver Dis"},{"issue":"1","key":"8085_CR46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/me.2005-0159","volume":"20","author":"JJ Eloranta","year":"2006","unstructured":"Eloranta JJ, Jung D, Kullak-Ublick GA (2006) The human Na + -taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol 20(1):65\u201379","journal-title":"Mol Endocrinol"},{"issue":"3","key":"8085_CR47","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/jhep.2003.50100","volume":"37","author":"D Jung","year":"2003","unstructured":"Jung D, Kullak-Ublick GA (2003) Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37(3):622\u2013631","journal-title":"Hepatology"},{"issue":"2","key":"8085_CR48","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.abb.2004.09.019","volume":"433","author":"JJ Eloranta","year":"2005","unstructured":"Eloranta JJ, Kullak-Ublick GA (2005) Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 433(2):397\u2013412","journal-title":"Arch Biochem Biophys"},{"issue":"7","key":"8085_CR49","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/S0016-5085(03)00388-3","volume":"124","author":"O Barbier","year":"2003","unstructured":"Barbier O, Torra IP, Sirvent A et al (2003) FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124(7):1926\u20131940","journal-title":"Gastroenterology"},{"issue":"10","key":"8085_CR50","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00008571-200410000-00001","volume":"14","author":"C Gnerre","year":"2004","unstructured":"Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA (2004) Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14(10):635\u2013645","journal-title":"Pharmacogenetics"},{"issue":"42","key":"8085_CR51","doi-asserted-by":"crossref","first-page":"29749","DOI":"10.1074\/jbc.274.42.29749","volume":"274","author":"J Grober","year":"1999","unstructured":"Grober J, Zaghini I, Fujii H et al (1999) Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor\/9-cis-retinoic acid receptor heterodimer. J Biol Chem 274(42):29749\u201329754","journal-title":"J Biol Chem"},{"issue":"6","key":"8085_CR52","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jhep.2006.03.006","volume":"44","author":"B Cariou","year":"2006","unstructured":"Cariou B, Staels B (2006) The expanding role of the bile acid receptor FXR in the small intestine. J Hepatol 44(6):1213\u20131215","journal-title":"J Hepatol"},{"issue":"3","key":"8085_CR53","doi-asserted-by":"crossref","first-page":"G476","DOI":"10.1152\/ajpgi.00430.2005","volume":"290","author":"JF Landrier","year":"2006","unstructured":"Landrier JF, Eloranta JJ, Vavricka SR, Kullak-Ublick GA (2006) The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes. Am J Physiol Gastrointest Liver Physiol 290(3):G476\u2013485","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"8085_CR54","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.20295","volume":"40","author":"E Neimark","year":"2004","unstructured":"Neimark E, Chen F, Li X, Shneider BL (2004) Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. Hepatology 40(1):149\u2013156","journal-title":"Hepatology"},{"issue":"17","key":"8085_CR55","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E et al (2002) 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 45(17):3569\u20133572","journal-title":"J Med Chem"},{"issue":"2","key":"8085_CR56","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.104.079665","volume":"313","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Clerici C, Antonelli E et al (2005) Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313(2):604\u2013612","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"8085_CR57","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","volume":"6","author":"B Goodwin","year":"2000","unstructured":"Goodwin B, Jones SA, Price RR et al (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6(3):517\u2013526","journal-title":"Mol Cell"},{"issue":"11","key":"8085_CR58","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","volume":"112","author":"Y Liu","year":"2003","unstructured":"Liu Y, Binz J, Numerick MJ et al (2003) Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112(11):1678\u20131687","journal-title":"J Clin Invest"},{"issue":"5","key":"8085_CR59","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Rizzo G et al (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127(5):1497\u20131512","journal-title":"Gastroenterology"},{"issue":"3","key":"8085_CR60","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0016-5085(03)01068-0","volume":"125","author":"M Wagner","year":"2003","unstructured":"Wagner M, Fickert P, Zollner G et al (2003) Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 125(3):825\u2013838","journal-title":"Gastroenterology"},{"issue":"30","key":"8085_CR61","doi-asserted-by":"crossref","first-page":"11323","DOI":"10.1073\/pnas.0604772103","volume":"103","author":"C Stedman","year":"2006","unstructured":"Stedman C, Liddle C, Coulter S et al (2006) Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci U S A 103(30):11323\u201311328","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"8085_CR62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0022-2275(20)30141-3","volume":"43","author":"SA Kliewer","year":"2002","unstructured":"Kliewer SA, Willson TM (2002) Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 43(3):359\u2013364","journal-title":"J Lipid Res"},{"issue":"21","key":"8085_CR63","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1073\/pnas.95.21.12208","volume":"95","author":"G Bertilsson","year":"1998","unstructured":"Bertilsson G, Heidrich J, Svensson K et al (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 95(21):12208\u201312213","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"8085_CR64","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","volume":"98","author":"JL Staudinger","year":"2001","unstructured":"Staudinger JL, Goodwin B, Jones SA et al (2001) The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A 98(6):3369\u20133374","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"8085_CR65","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1124\/jpet.107.124610","volume":"323","author":"HL Fang","year":"2007","unstructured":"Fang HL, Strom SC, Ellis E et al (2007) Positive and negative regulation of human hepatic hydroxysteroid sulfotransferase (SULT2A1) gene transcription by rifampicin: roles of hepatocyte nuclear factor 4alpha and pregnane X receptor. J Pharmacol Exp Ther 323(2):586\u2013598","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"8085_CR66","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.32.3.340","volume":"32","author":"D Gardner-Stephen","year":"2004","unstructured":"Gardner-Stephen D, Heydel JM, Goyal A et al (2004) Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32(3):340\u2013347","journal-title":"Drug Metab Dispos"},{"issue":"18","key":"8085_CR67","doi-asserted-by":"crossref","first-page":"14581","DOI":"10.1074\/jbc.M010173200","volume":"276","author":"A Geick","year":"2001","unstructured":"Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 276(18):14581\u201314587","journal-title":"J Biol Chem"},{"issue":"4","key":"8085_CR68","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1074\/jbc.M109326200","volume":"277","author":"HR Kast","year":"2002","unstructured":"Kast HR, Goodwin B, Tarr PT et al (2002) Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277(4):2908\u20132915","journal-title":"J Biol Chem"},{"issue":"11","key":"8085_CR69","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1124\/dmd.31.11.1296","volume":"31","author":"S Teng","year":"2003","unstructured":"Teng S, Jekerle V, Piquette-Miller M (2003) Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 31(11):1296\u20131299","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"8085_CR70","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bjp.0707235","volume":"151","author":"S Teng","year":"2007","unstructured":"Teng S, Piquette-Miller M (2007) Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. Br J Pharmacol 151(3):367\u2013376","journal-title":"Br J Pharmacol"},{"issue":"8638","key":"8085_CR71","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","volume":"1","author":"L Bachs","year":"1989","unstructured":"Bachs L, Pares A, Elena M, Piera C, Rodes J (1989) Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1(8638):574\u2013576","journal-title":"Lancet"},{"issue":"6","key":"8085_CR72","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/0016-5085(92)90335-V","volume":"102","author":"L Bachs","year":"1992","unstructured":"Bachs L, Pares A, Elena M, Piera C, Rodes J (1992) Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102(6):2077\u20132080","journal-title":"Gastroenterology"},{"issue":"2","key":"8085_CR73","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","volume":"129","author":"HU Marschall","year":"2005","unstructured":"Marschall HU, Wagner M, Zollner G et al (2005) Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129(2):476\u2013485","journal-title":"Gastroenterology"},{"issue":"3","key":"8085_CR74","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.20568","volume":"41","author":"K Dilger","year":"2005","unstructured":"Dilger K, Denk A, Heeg MH, Beuers U (2005) No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology 41(3):595\u2013602","journal-title":"Hepatology"},{"issue":"8","key":"8085_CR75","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","volume":"26","author":"S Khurana","year":"2006","unstructured":"Khurana S, Singh P (2006) Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 26(8):943\u2013948","journal-title":"Liver Int"},{"issue":"2","key":"8085_CR76","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/hep.20784","volume":"42","author":"M Wagner","year":"2005","unstructured":"Wagner M, Halilbasic E, Marschall HU et al (2005) CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42(2):420\u2013430","journal-title":"Hepatology"},{"issue":"3","key":"8085_CR77","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","volume":"46","author":"T Stojakovic","year":"2007","unstructured":"Stojakovic T, Putz-Bankuti C, Fauler G et al (2007) Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46(3):776\u2013784","journal-title":"Hepatology"},{"issue":"9","key":"8085_CR78","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/00365520310005172","volume":"38","author":"KM Boberg","year":"2003","unstructured":"Boberg KM, Egeland T, Schrumpf E (2003) Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol 38(9):991\u2013995","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"8085_CR79","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.bjp.0706992","volume":"150","author":"A Maier","year":"2007","unstructured":"Maier A, Zimmermann C, Beglinger C, Drewe J, Gutmann H (2007) Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol 150(3):361\u2013368","journal-title":"Br J Pharmacol"},{"issue":"7","key":"8085_CR80","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2007.03455.x","volume":"26","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Feagan BG, Lichtenstein GR (2007) Medical management of mild to moderate Crohn\u2019s disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther 26(7):987\u20131003","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"8085_CR81","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/j.1478-3231.2005.01122.x","volume":"25","author":"J Wiegand","year":"2005","unstructured":"Wiegand J, Schuler A, Kanzler S et al (2005) Budesonide in previously untreated autoimmune hepatitis. Liver Int 25(5):927\u2013934","journal-title":"Liver Int"},{"issue":"4","key":"8085_CR82","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","volume":"117","author":"M Leuschner","year":"1999","unstructured":"Leuschner M, Maier KP, Schlichting J et al (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117(4):918\u2013925","journal-title":"Gastroenterology"},{"issue":"4","key":"8085_CR83","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","volume":"41","author":"H Rautiainen","year":"2005","unstructured":"Rautiainen H, Karkkainen P, Karvonen AL et al (2005) Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 41(4):747\u2013752","journal-title":"Hepatology"},{"issue":"1","key":"8085_CR84","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","volume":"38","author":"W Hempfling","year":"2003","unstructured":"Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T (2003) Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38(1):196\u2013202","journal-title":"Hepatology"},{"issue":"1","key":"8085_CR85","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.53.1.78","volume":"53","author":"D Jung","year":"2004","unstructured":"Jung D, Fantin AC, Scheurer U, Fried M, Kullak-Ublick GA (2004) Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 53(1):78\u201384","journal-title":"Gut"},{"issue":"8","key":"8085_CR86","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0002-9270(00)01059-5","volume":"95","author":"HJ Hoogstraten van","year":"2000","unstructured":"van Hoogstraten HJ, Vleggaar FP, Boland GJ et al (2000) Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian\u2013Dutch PSC Study Group. Am J Gastroenterol 95(8):2015\u20132022","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"8085_CR87","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1111\/j.1572-0241.2000.02323.x","volume":"95","author":"P Angulo","year":"2000","unstructured":"Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD (2000) Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol 95(9):2333\u20132337","journal-title":"Am J Gastroenterol"},{"issue":"1\u20132","key":"8085_CR88","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2006.08.009","volume":"263","author":"D Lechner","year":"2007","unstructured":"Lechner D, Kallay E, Cross HS (2007) 1alpha,25-dihydroxyvitamin D3 downregulates CYP27B1 and induces CYP24A1 in colon cells. Mol Cell Endocrinol 263(1\u20132):55\u201364","journal-title":"Mol Cell Endocrinol"},{"key":"8085_CR89","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.mce.2006.12.014","volume":"265\u2013266","author":"MS Kim","year":"2007","unstructured":"Kim MS, Fujiki R, Kitagawa H, Kato S (2007) 1alpha,25(OH)2D3-induced DNA methylation suppresses the human CYP27B1 gene. Mol Cell Endocrinol 265\u2013266:168\u2013173","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"8085_CR90","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1093\/nar\/gkm179","volume":"35","author":"MM Turunen","year":"2007","unstructured":"Turunen MM, Dunlop TW, Carlberg C, Vaisanen S (2007) Selective use of multiple vitamin D response elements underlies the 1 alpha,25-dihydroxyvitamin D3-mediated negative regulation of the human CYP27B1 gene. Nucleic Acids Res 35(8):2734\u20132747","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"8085_CR91","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1210\/me.2005-0106","volume":"19","author":"TT Wang","year":"2005","unstructured":"Wang TT, Tavera-Mendoza LE, Laperriere D et al (2005) Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 19(11):2685\u20132695","journal-title":"Mol Endocrinol"},{"issue":"4","key":"8085_CR92","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00005176-200104000-00002","volume":"32","author":"BL Shneider","year":"2001","unstructured":"Shneider BL (2001) Intestinal bile acid transport: biology, physiology, and pathophysiology. J Pediatr Gastroenterol Nutr 32(4):407\u2013417","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1 Pt 1","key":"8085_CR93","first-page":"G157","volume":"274","author":"AL Craddock","year":"1998","unstructured":"Craddock AL, Love MW, Daniel RW et al (1998) Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol 274(1 Pt 1):G157\u2013169","journal-title":"Am J Physiol"},{"issue":"6","key":"8085_CR94","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1124\/mol.105.020792","volume":"69","author":"X Chen","year":"2006","unstructured":"Chen X, Chen F, Liu S et al (2006) Transactivation of rat apical sodium-dependent bile acid transporter and increased bile acid transport by 1alpha,25-dihydroxyvitamin D3 via the vitamin D receptor. Mol Pharmacol 69(6):1913\u20131923","journal-title":"Mol Pharmacol"},{"issue":"24","key":"8085_CR95","doi-asserted-by":"crossref","first-page":"23232","DOI":"10.1074\/jbc.M411520200","volume":"280","author":"TC McCarthy","year":"2005","unstructured":"McCarthy TC, Li X, Sinal CJ (2005) Vitamin D receptor-dependent regulation of colon multidrug resistance-associated protein 3 gene expression by bile acids. J Biol Chem 280(24):23232\u201323242","journal-title":"J Biol Chem"},{"issue":"5","key":"8085_CR96","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/carcin\/21.5.999","volume":"21","author":"V Kozoni","year":"2000","unstructured":"Kozoni V, Tsioulias G, Shiff S, Rigas B (2000) The effect of lithocholic acid on proliferation and apoptosis during the early stages of colon carcinogenesis: differential effect on apoptosis in the presence of a colon carcinogen. Carcinogenesis 21(5):999\u20131005","journal-title":"Carcinogenesis"},{"issue":"4","key":"8085_CR97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2133\/dmpk.21.315","volume":"21","author":"M Miyata","year":"2006","unstructured":"Miyata M, Matsuda Y, Tsuchiya H et al (2006) Chenodeoxycholic acid-mediated activation of the farnesoid X receptor negatively regulates hydroxysteroid sulfotransferase. Drug Metab Pharmacokinet 21(4):315\u2013323","journal-title":"Drug Metab Pharmacokinet"},{"issue":"5571","key":"8085_CR98","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1126\/science.1070477","volume":"296","author":"M Makishima","year":"2002","unstructured":"Makishima M, Lu TT, Xie W et al (2002) Vitamin D receptor as an intestinal bile acid sensor. Science 296(5571):1313\u20131316","journal-title":"Science"},{"issue":"4","key":"8085_CR99","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1210\/me.2005-0428","volume":"20","author":"CS Song","year":"2006","unstructured":"Song CS, Echchgadda I, Seo YK et al (2006) An essential role of the CAAT\/enhancer binding protein-alpha in the vitamin D-induced expression of the human steroid\/bile acid-sulfotransferase (SULT2A1). Mol Endocrinol 20(4):795\u2013808","journal-title":"Mol Endocrinol"},{"issue":"5","key":"8085_CR100","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1053\/jhep.2003.50176","volume":"37","author":"M Gascon-Barre","year":"2003","unstructured":"Gascon-Barre M, Demers C, Mirshahi A, Neron S, Zalzal S, Nanci A (2003) The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 37(5):1034\u20131042","journal-title":"Hepatology"},{"issue":"5","key":"8085_CR101","first-page":"649","volume":"20","author":"B Desvergne","year":"1999","unstructured":"Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20(5):649\u2013688","journal-title":"Endocr Rev"},{"issue":"8","key":"8085_CR102","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.bbalip.2007.04.021","volume":"1771","author":"F Zandbergen","year":"2007","unstructured":"Zandbergen F, Plutzky J (2007) PPARalpha in atherosclerosis and inflammation. Biochim Biophys Acta 1771(8):972\u2013982","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"8085_CR103","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","volume":"29","author":"J Itakura","year":"2004","unstructured":"Itakura J, Izumi N, Nishimura Y et al (2004) Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 29(4):216\u2013222","journal-title":"Hepatol Res"},{"issue":"6","key":"8085_CR104","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3748\/wjg.v10.i6.894","volume":"10","author":"K Dohmen","year":"2004","unstructured":"Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K (2004) Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 10(6):894\u2013898","journal-title":"World J Gastroenterol"},{"issue":"Suppl 3","key":"8085_CR105","doi-asserted-by":"crossref","first-page":"S515","DOI":"10.1111\/j.1872-034X.2007.00232.x","volume":"37","author":"S Iwasaki","year":"2007","unstructured":"Iwasaki S, Akisawa N, Saibara T, Onishi S (2007) Fibrate for treatment of primary biliary cirrhosis. Hepatol Res 37(Suppl 3):S515\u2013S517","journal-title":"Hepatol Res"},{"issue":"11","key":"8085_CR106","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1182\/blood-2003-11-3791","volume":"103","author":"R Kleemann","year":"2004","unstructured":"Kleemann R, Verschuren L, de Rooij BJ et al (2004) Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 103(11):4188\u20134194","journal-title":"Blood"},{"issue":"2","key":"8085_CR107","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2002-06-1762","volume":"101","author":"R Kleemann","year":"2003","unstructured":"Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T (2003) Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C\/EBP-beta complex formation. Blood 101(2):545\u2013551","journal-title":"Blood"},{"key":"8085_CR108","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1073\/pnas.0711281105","volume":"105","author":"D Panigraphy","year":"2008","unstructured":"Panigrahy D, Kaipainen A, Huang S, et al (2008) PPAR{alpha} agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. PNAS 105:985\u2013990","journal-title":"PNAS"},{"issue":"34","key":"8085_CR109","doi-asserted-by":"crossref","first-page":"30559","DOI":"10.1074\/jbc.M203511200","volume":"277","author":"D Jung","year":"2002","unstructured":"Jung D, Fried M, Kullak-Ublick GA (2002) Human apical sodium-dependent bile salt transporter (SLC10A2) gene is regulated by the peroxisome proliferator-activated receptor alpha. J Biol Chem 277(34):30559\u201330566","journal-title":"J Biol Chem"},{"issue":"8","key":"8085_CR110","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.bbalip.2007.03.006","volume":"1771","author":"S Heikkinen","year":"2007","unstructured":"Heikkinen S, Auwerx J, Argmann CA (2007) PPARgamma in human and mouse physiology. Biochim Biophys Acta 1771(8):999\u20131013","journal-title":"Biochim Biophys Acta"},{"issue":"22","key":"8085_CR111","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355(22):2297\u20132307","journal-title":"N Engl J Med"},{"issue":"6","key":"8085_CR112","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/hep.20705","volume":"41","author":"K Harada","year":"2005","unstructured":"Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y (2005) Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis. Hepatology 41(6):1329\u20131338","journal-title":"Hepatology"},{"key":"8085_CR113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-511X-6-3","volume":"6","author":"P Fickert","year":"2007","unstructured":"Fickert P, Moustafa T, Trauner M (2007) Primary sclerosing cholangitis\u2014the arteriosclerosis of the bile duct? Lipids Health Dis 6:3","journal-title":"Lipids Health Dis"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-008-8085-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-008-8085-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-008-8085-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T09:59:35Z","timestamp":1631699975000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-008-8085-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,28]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["8085"],"URL":"https:\/\/doi.org\/10.1007\/s12016-008-8085-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1122742.579815","asserted-by":"object"}]},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,28]]}}}